WALTHAM,
Mass., Nov. 5, 2024 /PRNewswire/ -- Q32 Bio Inc.
(Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company
focused on developing biologic therapeutics to restore immune
homeostasis, today announced that management will participate in a
fireside chat at 10:00 a.m. E.T. on Tuesday,
November 12, 2024 at Guggenheim's Inaugural Healthcare
Innovation Conference in Boston,
MA.
A webcast of the presentation will be available on the Events
and Presentations page of Q32 Bio's website at www.q32bio.com.
Archived replays will be available for 90 days following the
event.
About Q32 Bio
Q32 Bio is a clinical stage biotechnology company developing
biologic therapeutics targeting potent regulators of the innate and
adaptive immune systems to re-balance immunity in autoimmune and
inflammatory diseases. Q32 Bio's lead programs, focused on the IL-7
/ TSLP receptor pathways and complement system, address immune
dysregulation to help patients take back control of their
lives.
Q32 Bio's program for adaptive immunity, bempikibart (ADX-914),
is a fully human anti-IL-7Rα antibody that re-regulates adaptive
immune function for the treatment of autoimmune diseases. It is
being evaluated in two Phase 2 trials for the treatment of atopic
dermatitis and alopecia areata. The IL-7 and TSLP pathways have
been genetically and biologically implicated in driving several T
cell-mediated pathological processes in numerous autoimmune
diseases. Q32 Bio's program for innate immunity, ADX-097, is based
on a novel platform enabling tissue-targeted regulation of the
complement system without long-term systemic blockade – a
key differentiator versus current complement therapeutics. Q32
Bio has completed a first-in-human, Phase 1 ascending dose clinical
study of ADX-097 in healthy volunteers.
For more information, visit www.Q32Bio.com.
Availability of Other Information About Q32 Bio
Investors and others should note that we communicate with our
investors and the public using our company website www.Q32Bio.com,
including, but not limited to, company disclosures, investor
presentations and FAQs, Securities and Exchange Commission filings,
press releases, public conference call transcripts and webcast
transcripts, as well as on X (formerly Twitter) and LinkedIn. The
information that we post on our website or on X or LinkedIn could
be deemed to be material information. As a result, we encourage
investors, the media and others interested to review the
information that we post there on a regular basis. The contents of
our website or social media shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended.
Contacts:
Investors: Brendan
Burns
Media: Sarah Sutton
Argot Partners
212.600.1902
Q32Bio@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/q32-bio-to-participate-in-guggenheims-inaugural-healthcare-innovation-conference-302295851.html
SOURCE Q32 Bio